Latest news with #M42
Khaleej Times
5 days ago
- Health
- Khaleej Times
UAE: AI outperforms human radiologists, records zero false negatives
A comprehensive study on an AI model developed by Abu Dhabi-based healthcare group M42 has found that it can safely and accurately detect tuberculosis from chest X-rays — outperforming human radiologists. Published in the prestigious scientific journal npj Digital Medicine – Nature, the study conducted in collaboration with Abu Dhabi's Capital Health Screening Centre (CHSC) is among the largest real-world clinical validations of an AI-driven healthcare solution to date, analyzing over one million chest X-rays to evaluate the efficacy and scalability of AI in TB screening. The study assessed AI Radiology in Screening TB (AIRIS-TB), M42's cutting-edge AI model engineered to streamline routine tuberculosis screenings, allowing radiologists to focus on more complex or urgent cases. The model demonstrated exceptional performance, indicating high diagnostic accuracy and an unprecedented 0 percent of false negatives. This means that the model has the potential to safely automate up to 80 percent of routine chest X-ray assessments, directly reducing the workload of radiologists, minimising the risk of human error, and delivering significant cost efficiencies in high-throughput low-prevalence settings. Labour-intensive Currently, reviews of chest X-rays remains labor-intensive and prone to oversight and error, potentially leading to missed or delayed diagnoses. A prior study has indicated a 26.6 percent increase in missed findings when radiologists double their annotation speed, and a rise in errors after 9 hours into their shift. AIRIS-TB delivered consistently strong performance across a wide range of demographic groups, including variations in gender, age, HIV status, income levels, and a diverse population covering six World Health Organization (WHO) regions, highlighting the model's robustness, fairness and generalizability across diverse global populations. These results indicate the model's potential to significantly improve clinical workflows and drive earlier, more equitable screening of TB in high-volume programs worldwide. "This landmark study marks a pivotal moment in the potential power of AI in the global fight against tuberculosis,' said Dimitris Moulavasilis, Group CEO of M42. 'Our AIRIS-TB model stands as a compelling testament to the unmatched accuracy, safety and scalability that AI can deliver, particularly in resource-limited settings where there is a shortage of radiologists and the need to tackle TB is greatest.' He added that in regions with a high prevalence of TB, the model offers a 'scalable technological solution' that can help save lives. 'These results signal the transformative role AI can play in reshaping global public health and redefining how healthcare is diagnosed, delivered and experienced worldwide,' he said. The study underwent rigorous peer review and ethical oversight by the Department of Health – Abu Dhabi, ensuring transparency, accountability, and the highest standards of clinical integrity. Its publication in a leading scientific journal reinforces M42's position as a global pioneer in AI-led health solutions and solidifies the UAE's growing prominence as a global, data-driven hub for cutting-edge medical innovation and technology.
Zawya
5 days ago
- Health
- Zawya
M42 announces breakthrough results for its AI-powered tuberculosis screening
M42, a global health leader powered by technology, artificial intelligence (AI) and genomics, has unveiled landmark findings from a large-scale population study on AI-powered tuberculosis (TB) screening, published in the prestigious scientific journal npj Digital Medicine - Nature. Conducted in collaboration with Capital Health Screening Centre (CHSC) in Abu Dhabi, part of the M42 group, the study is among the largest real-world clinical validations of an AI-driven healthcare solution to date, analyzing over one million chest X-rays (CXRs) to evaluate the efficacy and scalability of AI in TB screening. The study assessed AI Radiology in Screening TB (AIRIS-TB), M42's cutting-edge AI model engineered to streamline routine tuberculosis screenings, allowing radiologists to focus on more complex or urgent cases. AIRIS-TB demonstrated exceptional performance, achieving an Area Under the Receiver Operating Characteristic Curve (AUROC) of 98.5% - a clear indicator of its high efficiency in triaging CXRs for TB. With an estimated 10.8 million people falling ill from TB and a total of 1.25 million people dying from it in 2023, according to the World Health Organisation (WHO), and recent reports of TB returning to being the world's leading cause of death from a single infectious agent, M42's AIRIS-TB demonstrates the potential of AI solutions delivering real-world impact. AIRIS-TB reported an unprecedented 0% false-negative rate for tuberculosis-specific cases across the full dataset – an achievement that reinforces its safety and reliability as a workflow automation tool. In practical application, the model has the potential to safely automate up to 80% of routine CXR assessments, directly alleviating radiologist workload pressures, minimising the risk of human error, and delivering significant cost efficiencies in high-throughput low-prevalence settings. Presently, CXR review remains labor-intensive and prone to oversight and error, potentially leading to missed or delayed diagnoses, with a prior study stating a 26.6% increase in missed findings when radiologists double their annotation speed, and a rise in errors after 9 hours into their shift. Importantly, AIRIS-TB delivered consistently strong performance across a wide range of demographic groups, including variations in gender, age, HIV status, income levels, and a diverse population covering six WHO regions, highlighting the model's robustness, fairness and generalisability across diverse global populations. These results underscore AIRIS-TB's potential to significantly enhance clinical workflows and drive earlier, more equitable screening of TB in high-volume programmes worldwide. Dimitris Moulavasilis, Group CEO of M42, said, "This landmark study marks a pivotal moment in the potential power of AI in the global fight against tuberculosis. Our AIRIS-TB model stands as a compelling testament to the unmatched accuracy, safety and scalability that AI can deliver, particularly in resource-limited settings where there is a shortage of radiologists and the need to tackle TB is greatest. In regions with a high prevalence of TB, we now have a scalable technological solution that can bridge the divide, expand radiologist capacity and help save lives. These results signal the transformative role AI can play in reshaping global public health and redefining how healthcare is diagnosed, delivered and experienced worldwide.' Dr. Laila Abdel Wareth, CEO of Capital Health Screening Centre, added, "The outcomes of this study reaffirm that AI models like AIRIS-TB can not only match – but safely surpass – human-level accuracy and efficiency in clinical practice. By automating high-volume, routine screenings with precision, we are equipping radiologists to concentrate on complex and high-risk cases, unlocking greater diagnostic capacity. This shift holds immense potential to elevate patient outcomes, streamline healthcare delivery and bolster public health infrastructure on a global scale." The study underwent rigorous peer review and ethical oversight by the Department of Health – Abu Dhabi, ensuring transparency, accountability, and the highest standards of clinical integrity. Its publication in a leading scientific journal reinforces M42's position as a global pioneer in AI-led health solutions and solidifies the UAE's growing prominence as a global, data-driven hub for cutting-edge medical innovation and technology. The full study is accessible through npj Digital Medicine.
The Sun
31-07-2025
- Automotive
- The Sun
M6 motorway closed in one direction after lorry goes up in flames with drivers warned of 60-minute delays
A MAJOR motorway is closed after a lorry caught on fire, causing significant delays. The M6 northbound is closed between J3A for Coleshill and J4 for the M42. 1 It has led to around five miles of congestion, with drivers being warned of long delays. Delays of around an hour can be expected. Motorists have been advised to plan alternative routes. A diversion via the M42 up to the J9 roundabout is in place. The incident occurred at around 4pm today, with pictures from National Highways showing fire crews tackling the blaze. A spokesperson for Birmingham Airport has warned that the delays could affect routes to the terminal. In addition to the M6 closure, the M42 and A4535 are also affected by closures amid "multiple ongoing road incidents".
New Indian Express
26-07-2025
- Science
- New Indian Express
Indian astronaut Shubhanshu Shukla shares stunning photographs of space
BENGALURU: Indian astronaut Shubhanshu Shukla, who returned from the International Space Station (ISS) recently after completing the Axiom-4 mission with three other astronauts, shared some of his stunning pictures of M42 (aka Orion Nebula), which he had taken from the Bengaluru sky. The Orion Nebula is an interstellar cloud of gas and dust that is located in the Orion constellation. Shux on X said as the photographs clicked on the ISS will take some time to be received, verified and cleared because of the multiple space agencies' involvement, he wanted to share his astrophotography story. 'I started into astrophotography upon returning to India after my first leg of training at the Gagarin Cosmonaut Training Centre (GCTC) in Russia. The pictures in sequence are of the same interstellar object M42 (M Stands for Messier- Name of the catalogue that maintains all night sky objects),' Shux posted. He added that over time, it has gotten better, and it is evident from the last photograph. 'All the pictures were clicked from the night sky of Bengaluru,' he posted on X. Shux, who has turned into an inspiration for students and the youth keen on the space fraternity, posted an encouraging message, 'Slow or fast, if you keep moving, progress is guaranteed.'
Newsweek
23-07-2025
- Health
- Newsweek
How the Future of AI Health Care is Taking Shape in the Middle East
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. For a look at how the health care of the future will be shaped by artificial intelligence and data, Abu Dhabi is a good start. The genetic makeup of most of the local population has been sequenced, allowing anyone's high risk of disease to be detected — and action to be taken — long before symptoms appear. Apps help patients navigate their care, with plans underway to connect them to everything from data delivered by wearable devices to medical records as well as to their doctors. "We use AI to predict conditions and improve medical outcomes and by improving outcomes, we're reducing hospitalization costs, reducing costs for the system," said Dimitris Moulavasilis, the chief executive of M42, a global health care company headquartered in the capital of the United Arab Emirates that underpins the health system there and is expanding rapidly abroad. "We're using genomics data to create population programs, which, again predict conditions, keep people healthy and we are using digital to organize health systems." "I think there is a wish across the globe that we should be able to improve the care delivered and reduce the cost. So how we can move from a reactive, episodic sick care where we are today." Dimitris Moulavasilis, CEO of Abu Dhabi-headquartered global health company M42 Dimitris Moulavasilis, CEO of Abu Dhabi-headquartered global health company M42 Courtesy of M42 Moulavasilis noted that health care costs vary from 7 to 8 percent of GDP in Eastern Europe to as high as 17 percent in the United States, but the costs are growing faster than economic growth rates everywhere. He said some of the biggest beneficiaries of data-driven and AI-powered health care would be in the less wealthy countries of the Global South that are starting from a lower base and can build their health systems in a more effective way. Personalized Treatments "Data plays a role as AI allows for personalized treatments, which allows patients to get treated, or you may predict conditions and patients might not get sick, and you can avoid the potential disease before it happens," he said, adding that it was also important considering increasing longevity. "People want to have a longer health span, not necessarily 200 years, but to live healthily until the end of their biological lives." M42 is already the largest health care group in the Middle East and serves some 15 million patients worldwide with operations in 27 countries. Its revenues have grown five times in the past seven years. M42 highlights examples of specific patients who have already been helped — such as a 40-year-old Emirati woman who was identified as having a 100 percent chance of thyroid cancer because of a gene mutation. She was treated straight away. Then there was the eight-year-old with vision loss, which was again pinned down to a gene mutation and treatment provided. "In Abu Dhabi, we have digitalized all the system. Digitalizing the system is not just applying some technologies, it is designing the systems and applying them. We are the engine behind the health information exchange," Moulavasilis said. M42 has an advantage being based in a center with a commitment to high-tech investment and to becoming a base for research, as well as with possibly the world's most extensive genome program by percentage of people covered — with more than 800,000 of 1.3 million Emiratis already sequenced and the number rising quickly. M42 runs the program in partnership with the Department of Health. Danat Al Emarat Hospital in Abu Dhabi Danat Al Emarat Hospital in Abu Dhabi M42 "They have the metrics, the people, the sophistication, and they are embracing all these new technologies, so we may try to deploy new models of care here, which then, upon the proof of the efficiency and outcomes we may expand globally," Moulavasilis said. "Because we have now all these amazing data sets, we have developed a trusted research environment that with the right privacy for the patient and keeping the data in a sovereign environment, we can extract insights and we can make collaborative research with pharma companies to create new targeted drugs and create new value from the life science space," Moulavasilis said. Genome Database For its genome database, it is recruiting patients across different sectors and genders to make its data sets fully representative, with models trained on different nationalities. At the same time, respect is paid to protecting individuals' and countries' rights to data privacy. M42's operations extend much further than Abu Dhabi. Through acquisitions and organic growth, it now has more than 480 facilities in 26 countries and over 20,000 employees. It foresees annual growth in the future at around 8 to 10 percent. Although M42 is not yet in the United States, it is investigating opportunities for investment there. It is already in most European countries and has a significant presence in Latin America, including Brazil and Chile. It also has a major presence close to home in Saudi Arabia and the Gulf countries. In Uzbekistan, it is collaborating and exploring opportunities for a strategic partnership on the Uzbek Genome Program. "The Global South really is an important space for expansion," Moulavasilis said, particularly after the acquisition of kidney-care provider Diaverum. "We are in discussion with many countries, particularly the Global South." M42's biggest challenge is not technology, it is human nurses and physicians, Moulavasilis said. There again, however, AI helps all to work more effectively. "As the population grows and ages, there's a big amount of nurses who the global national health systems lack today," he said. "Now we're privileged to be perceived as employees of choice because of the use of digital and AI, so nurses can be always very much productive, focusing what they are trained to do like provide care, as opposed to liaise with all the bureaucratic and the routine, non-valuable, mundane activities."
